九强生物 (300406)

Beijing Strong Biotechnologies, Inc

ASZ

Tags

AI HealthcareSpecialized-Sophisticated-Distinctive-Innovative EnterprisesCSI Central State-Owned Enterprises IndexArtificial Intelligence (AI)Pharmaceutical ManufacturingContains Convertible BondsHelicobacter PyloriPlanned Reduction of HoldingsEquity TransferMargin Trading and Securities LendingBidding TargetsHigh GoodwillHigh-Dividend Yield StocksChiNext 200 IndexChiNext 300 IndexChiNext Innovation

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 58630.86
  • Circulating A-Shares(W): 42441.65
  • Earnings Per Share(RMB): 0.4600
  • Net Assets Per Share(RMB): 6.5214
  • Operating Revenue(W RMB): 101171.39
  • Total Profit(W RMB): 30696.07
  • Net Profit Attributable to Parent(W RMB): 27246.08
  • Net Profit Growth Rate(%): -27.03
  • Weighted Return on Equity(%): 6.7300
  • Operating Cash Flow Per Share(RMB): 0.7280
  • Undistributed Profit Per Share(RMB): 4.5253
  • Capital Reserve Per Share(RMB): 0.5925

2. Main Business

The main business covers:

  • Production and sales of in vitro diagnostic reagents and instruments

3. Company Basic Information

  • Company Name: Beijing Strong Biotechnologies, Inc.
  • Listing Date: 2014-10-30
  • Industry: Pharmaceutical Manufacturing
  • Address: 5th Floor, Kuangyi Building, No. 15 Huayuan East Road, Haidian District, Beijing
  • Website: www.bsbe.com.cn
  • Company Profile: The issuer was established as a joint stock company through the overall change of Beijing Strong Biotechnologies Co., Ltd. On November 16, 2010, all promoters signed the "Promoter Agreement", agreeing to convert the audited net asset value of RMB 183.8042 million as of October 31, 2010 by Shenzhen Pengcheng into a share capital of RMB 100 million, with the remaining RMB 83.8042 million included in capital reserve. On January 13, 2011, the Beijing Municipal Commission of Commerce approved the change of Strong Limited to a foreign-invested joint stock company and renamed it Beijing Strong Biotechnologies, Inc., approving the promoter agreement and articles of association signed by the promoters on November 16, 2010. On March 15, 2011, Shenzhen Pengcheng verified the authenticity and legality of the company's registered capital as of March 15, 2011, and issued the "Capital Verification Report" (Shen Peng Suo Yan Zi [2011] No. 0084), confirming that all capital contributions subscribed by the promoters had been fully paid. On March 16, 2011, the promoters held the founding meeting of Strong Biotech. On March 17, 2011, the company completed the change registration at the Beijing Administration for Industry and Commerce and obtained the "Business License of Enterprise Legal Person" with registration number 110000002603153.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 China Pharmaceutical Investment Co., Ltd. General Legal Person 10841.85 25.55
2 Huabao CSI Medical ETF Fund 834.46 1.97
3 China Merchants Pharmaceutical Health Industry Stock Fund Fund 403.30 0.95
4 E Fund Anyang One-Year Holding Hybrid Securities Investment Fund Class A Fund 9.00 0.02
5 Changxin Robust Balanced 6-Month Holding Hybrid Securities Investment Fund Class A Fund 4.41 0.01
6 E Fund Hengxin Hybrid Securities Investment Fund Class A Fund 1.20 0.00

5. Concept Sectors

  • Convertible Bonds
  • Artificial Intelligence
  • Helicobacter Pylori
  • AI Healthcare
  • Margin Trading & Securities Lending
  • High Dividend Stocks
  • Being Acquired
  • Equity Transfer
  • Planned Reduction
  • High Goodwill
  • Specialized and Sophisticated SMEs
  • ChiNext 300
  • CSI Central SOEs
  • ChiNext Innovation
  • ChiNext 200

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information